Growth Metrics

KalVista Pharmaceuticals (KALV) FCF Margin (2014 - 2025)

KalVista Pharmaceuticals recorded quarterly FCF Margin of 95.88% in Q3 2025, up 74.09% quarter-over-quarter from 370.05% in Q2 2025.

KalVista Pharmaceuticals' FCF Margin history runs 8 years deep, the most recent figure standing at 95.88% for Q3 2025.

  • In Q3 2025, FCF Margin changed N/A year-over-year to 95.88%; the TTM figure through Jul 2025 stood at 188.05% (up 91507.0% YoY), while the FY2025 annual figure was 1394.56%, down 121602.0% from the prior year.
  • FCF Margin came in at 95.88% for Q3 2025 at KalVista Pharmaceuticals, up from 370.05% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 95.88% in Q3 2025 to a low of 370.05% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -3.98%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 43.35%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.53%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.17%
10 KalVista Pharmaceuticals 1.44 Bn 1.25 Bn 56.41 Mn -95.88%

Historic Data

Download Data 🔒
DateValue
Jul 31, 2025 -95.88%
Apr 30, 2025 -370.05%
Apr 30, 2020 -330.18%
Jan 31, 2020 -831.26%
Oct 31, 2019 -202.24%
Jul 31, 2019 -337.58%
Apr 30, 2019 -368.63%
Jan 31, 2019 -279.59%
Oct 31, 2018 -161.07%
Jul 31, 2018 -182.28%
Apr 30, 2018 -145.43%
Jan 31, 2018 1,202.83%
Oct 31, 2017 -648.62%
Jul 31, 2017 -4,747.92%
Apr 30, 2017 -2,322.81%
Jan 31, 2017 -4,535.08%
Oct 31, 2016 -2,134.01%
Jul 31, 2016 -584.31%
Mar 31, 2016 -75,257.14%
Dec 31, 2015 -77,800.00%
Sep 30, 2015 -76,100.00%
Jun 30, 2015 -93,142.86%
Mar 31, 2015 -60,414.29%
Sep 30, 2014 -32,310.00%
Jun 30, 2014 -40,260.00%
Mar 31, 2014 -29,250.00%